Meeting
2014 ASCO Annual Meeting
BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.
Authors
Philip C. Schouten
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Philip C. Schouten , Oleg Gluz , Nadia Harbeck , Svjetlana Mohrmann , Raihana Diallo-Danebrock , Enrico Pelz , Janneke Kruizinga , Arno Velds , Marja Nieuwland , Ron M. Kerkhoven , Cornelia Liedtke , Markus Frick , Ronald Kates , Sabine C. Linn , Ulrike Nitz , Frederik Marme
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11018)
DOI
10.1200/jco.2014.32.15_suppl.11018
Abstract #
11018
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
BRCA1 like copy number profiles to predict benefit of intensified alkylating chemotherapy in breast cancer.
First Author: Philip C. Schouten
Poster
2021 ASCO Annual Meeting
Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.
First Author: Ignacio Ortego
Poster
2017 ASCO Annual Meeting
The role of high-dose chemotherapy (CT) and stem-cell support in high-risk stage II, locally advanced, and responding stage IV breast cancer (BC): The Israeli experience with 20 years median follow-up.
First Author: Idit Peretz
Poster
2017 ASCO Annual Meeting
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).
First Author: Jenny Furlanetto